Positive impactSector
Pharma stocks rise up to 5% as US exempts select specialty drugs from 100% tariff; Mankind Pharma, Dr Reddy’s lead
Fortune India 1 hr ago·29 Sept 2026, 9:29 am
Mankind Pharma shares surged over 5% after the US government exempted select specialty drugs from proposed tariffs. This policy shift, which also boosted other pharma stocks, eases concerns over potential trade barriers for key exports. The exemption is a positive development for Indian drugmakers, as it reduces the risk of higher costs and lower demand in the US market.
For investors, this news is a relief, signaling that the US administration is considering the supply chain impact on essential medicines. It suggests a more nuanced approach to trade policy rather than a blanket restriction. The move highlights the strategic importance of the US market for Indian pharmaceutical companies.
Investors should monitor the final list of exempted drugs and any subsequent policy announcements. The company's ability to maintain its pricing power and supply chain efficiency will remain critical. Keep an eye on broader trade relations and how this exemption fits into the larger economic strategy.
Excerpt from Fortune India
Pharma stocks emerged as the top-performing sectoral indices in an otherwise weak market on Tuesday, with the Nifty Pharma rising nearly 1% after the US exempted select specialty pharmaceutical products and ingredients from its 100% tariff regime. In an overnight development, the US exempted select specialty…Read the original at Fortune India
Affected stocks
Bullish1 stock
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Mankind Pharma (MANKIND).
- Category: Sector.
- AI reads the tone as positive (potentially bullish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update for Mankind Pharma worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
